As­traZeneca makes case for use of blood thin­ner Bril­in­ta in stroke pa­tients

As­traZeneca’s ex­trav­a­gant pro­jec­tions for its clot fight­er Bril­in­ta may have fiz­zled in the face of un­der­whelm­ing tri­al da­ta — but a new piv­otal study is set to ex­pand its use sub­stan­tial­ly.

On Mon­day, the British drug­mak­er said the drug, when tak­en in con­junc­tion with as­pirin, in­duced a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in the risk of the pri­ma­ry com­pos­ite end­point of stroke and death, com­pared to as­pirin alone, in 11,000 pa­tients that have suf­fered mi­nor acute is­chemic stroke or a high-risk tran­sient is­chemic at­tack (TIA).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER